Unison Advisors LLC Purchases 1,717 Shares of Pfizer Inc. $PFE

Unison Advisors LLC boosted its stake in Pfizer Inc. (NYSE:PFE) by 1.9% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 92,115 shares of the biopharmaceutical company’s stock after purchasing an additional 1,717 shares during the quarter. Unison Advisors LLC’s holdings in Pfizer were worth $2,233,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of the business. GKV Capital Management Co. Inc. bought a new stake in Pfizer during the first quarter worth $27,000. North Capital Inc. purchased a new position in Pfizer in the 1st quarter valued at approximately $28,000. Bayforest Capital Ltd bought a new stake in shares of Pfizer during the 1st quarter valued at $28,000. Harbor Asset Planning Inc. bought a new stake in Pfizer during the 2nd quarter worth approximately $29,000. Finally, Horizon Financial Services LLC bought a new stake in Pfizer during the first quarter valued at $35,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Trading Up 1.2%

Pfizer stock opened at $24.52 on Monday. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. The stock has a market cap of $139.38 billion, a P/E ratio of 13.04, a PEG ratio of 0.81 and a beta of 0.55. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $29.36. The firm’s 50 day moving average price is $24.89 and its 200-day moving average price is $24.11.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The firm had revenue of $14.65 billion for the quarter, compared to the consensus estimate of $13.43 billion. During the same period in the previous year, the firm posted $0.60 EPS. The business’s quarterly revenue was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, equities analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 7th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 7.0%. The ex-dividend date of this dividend is Friday, November 7th. Pfizer’s dividend payout ratio (DPR) is presently 91.49%.

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. Wall Street Zen cut shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday, September 28th. Weiss Ratings reissued a “hold (c-)” rating on shares of Pfizer in a research report on Wednesday, October 8th. Morgan Stanley reduced their price objective on shares of Pfizer from $33.00 to $32.00 and set an “equal weight” rating on the stock in a research report on Friday, October 10th. Bank of America raised their price objective on Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research report on Friday, October 3rd. Finally, UBS Group restated a “neutral” rating and issued a $28.00 price target on shares of Pfizer in a research note on Wednesday, October 1st. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $28.13.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.